Advancing oncology clinical development in India — U.S. governance, executed locally.
eteraflex connects is a clinical development strategy firm with in-house FDA and DCGI regulatory expertise and a DCGI-registered CRO in India. We set the regulatory, CMC, and operational strategy that gets oncology programs to market — then execute it through premier Indian oncology sites.
U.S. governance
In-house FDA + DCGI regulatory
DCGI-registered CRO
Premier oncology sites
Designed to EMA, PMDA, MFDS & NMPA standard
Strategy first. Then we run it.
We are a clinical development strategy firm that can also execute. Most CROs run the protocol you bring; we tell you — before you commit — whether the regulatory pathway, the CMC plan, and the operational design are right, and we have the in-house DCGI-registered capability to run it when India is the answer. Strategy leads. Execution is the proof.
Regulatory & CMC strategy across major agencies
One development plan designed to hold across the FDA, EMA, PMDA, MFDS, NMPA and India’s DCGI, with CMC aligned to the filing and the Subject Expert Committee anticipated from the start.
Premier oncology sites & enrollment
execution through premier, high-volume Indian oncology centers, with biomarker and tissue logistics designed in to break the enrollment bottleneck where oncology programs stall.
One accountable team
strategy and execution under one roof and one DCGI-registered CRO: fewer handoffs, one owner from protocol to database lock
Enabling oncology clinical development in India — strategy and execution under one roof
eteraflex connects bridges U.S. clinical governance with India’s research ecosystem for small to mid-cap biotechnology and medical-device innovators. We lead with the regulatory, CMC, and operational decisions that determine whether an oncology program reaches its markets — then execute them through premier oncology sites under our DCGI-registered CRO.
Our Core Offerings
Aligned to your strategy. Built for execution.
Regulatory Strategy (multi-region)
one regulatory strategy across the FDA, EMA, PMDA, MFDS, NMPA and India’s DCGI, set by an in-house team.
CMC Advisory
manufacturing and quality strategy built into the regulatory filing, not bolted on before submission.
Clinical Operations
full delivery through premier Indian oncology sites under our DCGI-registered CRO, with patient-access and enrollment acceleration.
FSP / FSO Clinical Science Pods
embed an expert medical, scientific, and operational pod into your global program without giving up control.
India Market & Licensing Strategy
whether, when, and how to enter India, from a firm that operates there.
Commercial Foresight Engine
before you commit an asset, know whether it wins: access, competition, and value across the US and India.
Why Choose eteraflex connects
Stratergy-led. Execution-ready. Built for oncology.
Competitive Cost Structure
45-65% cost reduction compared to US and European markets – Transparent pricing with performance-based fee structures – Guaranteed 4-6X ROI within 12 months for FSP programs – Complete financial predictability without hidden costs
Proven Regulatory Excellence
4-5 week approvals (vs. 12-16 week industry average) – 98% first-submission approval rate – 150+ successful regulatory clearances – Zero critical audit findings over 24 months
Our Infrastructure
450+ dedicated professionals across validated networks – 240+ active clinical research sites nationwide – 180+ experienced investigators across therapeutic areas – Dual-sector expertise serving biotechnology and medical device sectors
In-house FDA + DCGI regulatory expertise, designing to EMA, PMDA, MFDS and NMPA standards.
A DCGI-registered CRO and premier oncology sites in India.
Oncology depth and a real answer to the enrollment bottleneck.
Strategy and execution under one accountable roof, from protocol to database lock.
Our Clinical Research Organization (CRO)delivers
Global expertise, regulatory excellence, and operational efficiency to accelerate successful clinical research outcomes.
Global Collaboration:
US-based leadership and India-based operational teams delivering seamless execution and cost-effective outcomes.
Regulatory Expertise:
Strong understanding of CDSCO requirements with proven experience in regulatory submissions and effective stakeholder engagement.
Commitment to Quality:
Consistent focus on quality with a 100% inspection success rate across completed clinical programs.
Scalable Operations:
Robust enterprise-grade infrastructure complemented by personalized support and dedicated client engagement for every project
lorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusumlorem impusum
Global expertise, regulatory depth, and operational discipline — under one accountable relationship.
U.S.-based leadership and India-based operations; in-house FDA and DCGI regulatory expertise; a DCGI-registered CRO for execution; and a consistent, inspection-ready standard across every engagement.
End-to-end clinical research across all phases. 240+ sites, 100% inspection pass rate.